Fly News Breaks for March 2, 2015
PTCT
Mar 2, 2015 | 06:32 EDT
JPMorgan downgraded PTC Therapeutics to Neutral citing valuation following the recent rally in shares. The firm says that while PTC could be an attractive asset to many potential companies, the price paid is unlikely to be significantly higher than current levels. It raised its price target for the stock to $65 from $56.
News For PTCT From the Last 2 Days
There are no results for your query PTCT